Skip to main content

Table 7 Terminal measurements after systemic in vivo pravastatin treatment

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Week 12 CKD ( n = 6) CKD + pravastatin ( n = 5)
Body weight (g) 357 ± 24 369 ± 16
Heart weight (g/100 g BW) 0.45 ± 0.02 0.42 ± 0.03*
Kidney weight (g/100 g BW) 0.57 ± 0.02 0.57 ± 0.04
MAP (mmHg) 168 ± 19 164 ± 19
GFR (μl/minute/100 g) 340 ± 60 332 ± 41
ERPF(μl/minute/100 g) 1335 ± 291 1221 ± 189
Hematocrit 0.41 ± 0.02 0.40 ± 0.02
FF (%) 28 ± 3 26 ± 2
Cholesterol (mmol/l) 2.89 ± 0.53 2.73 ± 0.46
Triglycerides (mmol/l) 1.42 ± 0.38 0.70 ± 0.37*
Fold change hepatic HMGCR mRNA expression 1.000 ± 0.56 1.584 ± 0.65
  1. Data presented as mean ± standard deviation. BW, body weight; CKD, chronic kidney disease; ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; MAP, mean arterial pressure. *P <0.05 compared with CKD.